Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK513059PMID: 30000989
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 1269440-17-6
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the clinical use of encorafenib during breastfeeding. The manufacturer recommends that breastfeeding be discontinued during encorafenib therapy and for at least 2 weeks after the final dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Encorafenib
CAS Registry Number
1269440-17-6
Drug Class
Breast Feeding
Lactation
Antineoplastic Agents
Enzyme Inhibitors
Protein Kinase Inhibitors
Signal Transduction Inhibitors
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Review Binimetinib.[Drugs and Lactation Database (...]Review Binimetinib.. Drugs and Lactation Database (LactMed®). 2006
- Encorafenib Acts as a Dual-Activity Chemosensitizer through Its Inhibitory Effect on ABCC1 Transporter In Vitro and Ex Vivo.[Pharmaceutics. 2022]Encorafenib Acts as a Dual-Activity Chemosensitizer through Its Inhibitory Effect on ABCC1 Transporter In Vitro and Ex Vivo.Zhang Y, Vagiannis D, Budagaga Y, Sabet Z, Hanke I, Rozkoš T, Hofman J. Pharmaceutics. 2022 Nov 24; 14(12). Epub 2022 Nov 24.
- Review Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma.[Drugs Today (Barc). 2019]Review Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma.Rose AAN. Drugs Today (Barc). 2019 Apr; 55(4):247-264.
- Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma.[Clin Cancer Res. 2017]Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma.Delord JP, Robert C, Nyakas M, McArthur GA, Kudchakar R, Mahipal A, Yamada Y, Sullivan R, Arance A, Kefford RF, et al. Clin Cancer Res. 2017 Sep 15; 23(18):5339-5348. Epub 2017 Jun 13.
- Review Ribociclib.[Drugs and Lactation Database (...]Review Ribociclib.. Drugs and Lactation Database (LactMed®). 2006
- Encorafenib - Drugs and Lactation Database (LactMed®)Encorafenib - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...